241 related articles for article (PubMed ID: 28454982)
1. Dopamine transporter (DAT) genetic hypofunction in mice produces alterations consistent with ADHD but not schizophrenia or bipolar disorder.
Mereu M; Contarini G; Buonaguro EF; Latte G; Managò F; Iasevoli F; de Bartolomeis A; Papaleo F
Neuropharmacology; 2017 Jul; 121():179-194. PubMed ID: 28454982
[TBL] [Abstract][Full Text] [Related]
2. Amphetamine-induced locomotion in a hyperdopaminergic ADHD mouse model depends on genetic background.
O'Neill B; Gu HH
Pharmacol Biochem Behav; 2013 Jan; 103(3):455-9. PubMed ID: 23026058
[TBL] [Abstract][Full Text] [Related]
3. Dopamine-mediated immunomodulation affects choroid plexus function.
Castellani G; Contarini G; Mereu M; Albanesi E; Devroye C; D'Amore C; Ferretti V; De Martin S; Papaleo F
Brain Behav Immun; 2019 Oct; 81():138-150. PubMed ID: 31175999
[TBL] [Abstract][Full Text] [Related]
4. Impaired cliff avoidance reaction in dopamine transporter knockout mice.
Yamashita M; Sakakibara Y; Hall FS; Numachi Y; Yoshida S; Kobayashi H; Uchiumi O; Uhl GR; Kasahara Y; Sora I
Psychopharmacology (Berl); 2013 Jun; 227(4):741-9. PubMed ID: 23397052
[TBL] [Abstract][Full Text] [Related]
5. [Neuronal development of the hyperdopaminergic animal model].
Kasahara Y; Arime Y; Kubo Y; Fukui A; Sora I
Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Nov; 31(5-6):195-9. PubMed ID: 22256607
[TBL] [Abstract][Full Text] [Related]
6. Functional coding variation in the presynaptic dopamine transporter associated with neuropsychiatric disorders drives enhanced motivation and context-dependent impulsivity in mice.
Davis GL; Stewart A; Stanwood GD; Gowrishankar R; Hahn MK; Blakely RD
Behav Brain Res; 2018 Jan; 337():61-69. PubMed ID: 28964912
[TBL] [Abstract][Full Text] [Related]
7. Neuropsychiatric disease-associated genetic variants of the dopamine transporter display heterogeneous molecular phenotypes.
Herborg F; Andreassen TF; Berlin F; Loland CJ; Gether U
J Biol Chem; 2018 May; 293(19):7250-7262. PubMed ID: 29559554
[TBL] [Abstract][Full Text] [Related]
8. Serotonin/dopamine interactions in a hyperactive mouse: reduced serotonin receptor 1B activity reverses effects of dopamine transporter knockout.
Hall FS; Sora I; Hen R; Uhl GR
PLoS One; 2014; 9(12):e115009. PubMed ID: 25514162
[TBL] [Abstract][Full Text] [Related]
9. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice.
Barr AM; Lehmann-Masten V; Paulus M; Gainetdinov RR; Caron MG; Geyer MA
Neuropsychopharmacology; 2004 Feb; 29(2):221-8. PubMed ID: 14603268
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of dopamine transporter knockout mice as an animal model of AD/HD].
Kasahara Y; Kubo Y; Sora I
Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):185-9. PubMed ID: 25069256
[TBL] [Abstract][Full Text] [Related]
11. Novelty-related behavior of young and adult dopamine transporter knockout rats: Implication for cognitive and emotional phenotypic patterns.
Adinolfi A; Carbone C; Leo D; Gainetdinov RR; Laviola G; Adriani W
Genes Brain Behav; 2018 Apr; 17(4):e12463. PubMed ID: 29406596
[TBL] [Abstract][Full Text] [Related]
12. Pronounced Hyperactivity, Cognitive Dysfunctions, and BDNF Dysregulation in Dopamine Transporter Knock-out Rats.
Leo D; Sukhanov I; Zoratto F; Illiano P; Caffino L; Sanna F; Messa G; Emanuele M; Esposito A; Dorofeikova M; Budygin EA; Mus L; Efimova EV; Niello M; Espinoza S; Sotnikova TD; Hoener MC; Laviola G; Fumagalli F; Adriani W; Gainetdinov RR
J Neurosci; 2018 Feb; 38(8):1959-1972. PubMed ID: 29348190
[TBL] [Abstract][Full Text] [Related]
13. Nicotine improves cognitive deficits of dopamine transporter knockout mice without long-term tolerance.
Weiss S; Nosten-Bertrand M; McIntosh JM; Giros B; Martres MP
Neuropsychopharmacology; 2007 Dec; 32(12):2465-78. PubMed ID: 17375139
[TBL] [Abstract][Full Text] [Related]
14. Region-specific dendritic spine loss of pyramidal neurons in dopamine transporter knockout mice.
Kasahara Y; Arime Y; Hall FS; Uhl GR; Sora I
Curr Mol Med; 2015; 15(3):237-44. PubMed ID: 25817859
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine.
Uchiumi O; Kasahara Y; Fukui A; Hall FS; Uhl GR; Sora I
Neuropharmacology; 2013 Jan; 64():348-56. PubMed ID: 22809709
[TBL] [Abstract][Full Text] [Related]
16. Chronic exposure to ethanol of male mice before mating produces attention deficit hyperactivity disorder-like phenotype along with epigenetic dysregulation of dopamine transporter expression in mouse offspring.
Kim P; Choi CS; Park JH; Joo SH; Kim SY; Ko HM; Kim KC; Jeon SJ; Park SH; Han SH; Ryu JH; Cheong JH; Han JY; Ko KN; Shin CY
J Neurosci Res; 2014 May; 92(5):658-70. PubMed ID: 24510599
[TBL] [Abstract][Full Text] [Related]
17. Single Quantum Dot Imaging Reveals PKCβ-Dependent Alterations in Membrane Diffusion and Clustering of an Attention-Deficit Hyperactivity Disorder/Autism/Bipolar Disorder-Associated Dopamine Transporter Variant.
Thal LB; Tomlinson ID; Quinlan MA; Kovtun O; Blakely RD; Rosenthal SJ
ACS Chem Neurosci; 2019 Jan; 10(1):460-471. PubMed ID: 30153408
[TBL] [Abstract][Full Text] [Related]
18. Brexpiprazole reduces hyperactivity, impulsivity, and risk-preference behavior in mice with dopamine transporter knockdown-a model of mania.
Milienne-Petiot M; Geyer MA; Arnt J; Young JW
Psychopharmacology (Berl); 2017 Mar; 234(6):1017-1028. PubMed ID: 28160035
[TBL] [Abstract][Full Text] [Related]
19. Loss of striatal cannabinoid CB1 receptor function in attention-deficit / hyperactivity disorder mice with point-mutation of the dopamine transporter.
Castelli M; Federici M; Rossi S; De Chiara V; Napolitano F; Studer V; Motta C; Sacchetti L; Romano R; Musella A; Bernardi G; Siracusano A; Gu HH; Mercuri NB; Usiello A; Centonze D
Eur J Neurosci; 2011 Nov; 34(9):1369-77. PubMed ID: 22034972
[TBL] [Abstract][Full Text] [Related]
20. Is dopamine transporter-mediated dopaminergic signaling in the retina a noninvasive biomarker for attention-deficit/ hyperactivity disorder? A study in a novel dopamine transporter variant Val559 transgenic mouse model.
Dai H; Jackson CR; Davis GL; Blakely RD; McMahon DG
J Neurodev Disord; 2017 Dec; 9(1):38. PubMed ID: 29281965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
